Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Atossa Therapeutics Inc (ATOS)

Atossa Therapeutics Inc (ATOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 121,234
  • Shares Outstanding, K 125,801
  • Annual Sales, $ 0 K
  • Annual Income, $ -30,090 K
  • EBIT $ -30 M
  • EBITDA $ -29 M
  • 60-Month Beta 1.21
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.67
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.21
  • Most Recent Earnings $-0.05 on 11/12/24
  • Next Earnings Date 11/11/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 164.42% ( +35.48%)
  • Historical Volatility 59.25%
  • IV Percentile 91%
  • IV Rank 54.58%
  • IV High 273.36% on 04/05/24
  • IV Low 33.52% on 09/10/24
  • Put/Call Vol Ratio 1.72
  • Today's Volume 144
  • Volume Avg (30-Day) 289
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 21,293
  • Open Int (30-Day) 19,662

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.06
  • Number of Estimates 2
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year -0.06
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9600 +0.39%
on 12/20/24
1.3600 -29.14%
on 11/25/24
-0.2363 (-19.69%)
since 11/20/24
3-Month
0.9600 +0.39%
on 12/20/24
1.6600 -41.95%
on 11/11/24
-0.4963 (-33.99%)
since 09/20/24
52-Week
0.7200 +33.85%
on 12/21/23
2.3100 -58.28%
on 04/05/24
+0.2357 (+32.38%)
since 12/20/23

Most Recent Stories

More News
Atossa Therapeutics Announces Discovery of Synergistic Compounds for (Z)-Endoxifen in Breast Cancer Treatment

Atossa Therapeutics announced data on new compounds potentially effective in combination with (Z)-endoxifen for breast cancer treatment.Quiver AI SummaryAtossa Therapeutics, Inc. announced the discovery...

ATOS : 0.9637 (-1.66%)
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

ATOS : 0.9637 (-1.66%)
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

ATOS : 0.9637 (-1.66%)
Atossa Therapeutics Presents Promising Phase 2 EVANGELINE Trial Data on (Z)-Endoxifen for Breast Cancer at SABCS 2024

Atossa Therapeutics presents Phase 2 EVANGELINE trial data on (Z)-endoxifen at SABCS 2024, focusing on breast cancer treatment.Quiver AI SummaryAtossa Therapeutics, Inc. has announced the presentation...

ATOS : 0.9637 (-1.66%)
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

ATOS : 0.9637 (-1.66%)
Atossa Therapeutics Presents Research on Anti-Cancer Activity of (Z)-Endoxifen and Byproducts at AACR Special Conference

Atossa Therapeutics presented research on (Z)-endoxifen's anti-cancer effects at the AACR conference, highlighting potential treatment options.Quiver AI SummaryAtossa Therapeutics, Inc. announced the presentation...

ATOS : 0.9637 (-1.66%)
Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research

ATOS : 0.9637 (-1.66%)
Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

ATOS : 0.9637 (-1.66%)
Atossa Therapeutics Announces Five Abstracts Accepted for Presentation at SABCS 2024 Featuring (Z)-Endoxifen Data in Breast Cancer Research

Atossa Therapeutics announced five accepted abstracts on (Z)-endoxifen for the San Antonio Breast Cancer Symposium in December 2024.Quiver AI SummaryAtossa Therapeutics, a clinical-stage biopharmaceutical...

ATOS : 0.9637 (-1.66%)
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

ATOS : 0.9637 (-1.66%)

Business Summary

Atossa Genetics Inc. is a healthcare company focused on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer. The Company's diagnostic tests consist of medical devices which can collect fluid samples from the breast milk ducts. It is also conducting...

See More

Key Turning Points

3rd Resistance Point 1.0625
2nd Resistance Point 1.0412
1st Resistance Point 1.0025
Last Price 0.9637
1st Support Level 0.9425
2nd Support Level 0.9212
3rd Support Level 0.8825

See More

52-Week High 2.3100
Fibonacci 61.8% 1.7026
Fibonacci 50% 1.5150
Fibonacci 38.2% 1.3274
Last Price 0.9637
52-Week Low 0.7200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar